WEST CHESTER, Ohio--(BUSINESS WIRE)--May 28, 2014--
AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical
device provider, today announced that it will present at the 9th
Annual JMP Securities Healthcare Conference at The Westin New York Grand
Central on Tuesday, June 24, 2014. Management is scheduled to present
at 1:30 p.m. Eastern Time.
A live audio webcast and replay of the presentation will be available
for 90 days following the presentation at http://wsw.com/webcast/jmp24/ATRC.
About AtriCure, Inc.
Inc. is a medical device company providing innovative atrial
fibrillation (Afib) solutions designed to produce superior outcomes that
reduce the economic and social burden of atrial fibrillation. AtriCure’s
Synergy Ablation System is the first and only device approved for the
treatment of Persistent and Longstanding Persistent forms of Afib in
patients undergoing certain open concomitant procedures. AtriCure’s
AtriClip Left Atrial Appendage (LAA) exclusion device is the most widely
implanted device for LAA management worldwide. The company believes
cardiothoracic surgeons are adopting its ablation and LAA management
devices for the treatment of Afib and reduction of Afib related
complications such as stroke. Afib affects more than 5.5 million people
Source: AtriCure, Inc.
Andy Wade, Vice President and Chief Financial
Lynn Pieper, 415-202-5678